

Nicolás Merchante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7717498/publications.pdf>

Version: 2024-02-01

75
papers

2,292
citations

279701

23
h-index

233338

45
g-index

79
all docs

79
docs citations

79
times ranked

3159
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
2	Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. <i>Aids</i> , 2006, 20, 49-57.	1.0	154
3	Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C. <i>Aids</i> , 2004, 18, 767-774.	1.0	143
4	Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus-Infected Patients With Compensated Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 56, 1646-1653.	2.9	77
5	High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. <i>Liver International</i> , 2008, 28, 781-786.	1.9	76
6	Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. <i>Hepatology</i> , 2012, 56, 228-238.	3.6	76
7	Natural History of Compensated Hepatitis C Virus-Related Cirrhosis in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1274-1282.	2.9	66
8	Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. <i>Clinical Infectious Diseases</i> , 2013, 56, 143-150.	2.9	62
9	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Cut</i> , 2022, 71, 593-604.	6.1	62
10	Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients. <i>Aids</i> , 2014, 28, 1931-1937.	1.0	52
11	Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 839-846.	0.6	48
12	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015, 71, 571-577.	1.7	42
13	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2017, 65, 1012-1019.	2.9	42
14	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , 2020, 7, e565-e573.	2.1	42
15	Prevalence and Risk Factors for Abnormal Liver Stiffness in HIV-infected Patients without Viral Hepatitis Coinfection: Role of Didanosine. <i>Antiviral Therapy</i> , 2010, 15, 753-763.	0.6	41
16	Incidence of and Risk Factors for Insulin Resistance in Treatment-Naive HIV-Infected Patients 48 Weeks after Starting Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 529-535.	0.6	38
17	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2012, 56, 1261-1270.	3.6	37
18	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	0.8	36

#	ARTICLE	IF	CITATIONS
19	Increased Hepatocyte Fas Expression and Apoptosis in HIV and Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1566-1576.	1.9	33
20	Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV. <i>PLoS ONE</i> , 2013, 8, e68953.	1.1	32
21	HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014, 28, 41-47.	1.0	30
22	Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2204-2211.	1.3	29
23	Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. <i>Gut</i> , 2009, 58, 1654-1660.	6.1	23
24	Reassessment of Genotype 1 Hepatitis C Virus Subtype Misclassification by LiPA 2.0: Implications for Direct-Acting Antiviral Treatment. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4027-4029.	1.8	23
25	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016, 17, 766-773.	1.0	23
26	Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. <i>Clinical Infectious Diseases</i> , 2020, 71, 2354-2362.	2.9	23
27	Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. <i>Aids</i> , 2017, 31, 493-500.	1.0	22
28	Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0210721.	1.4	22
29	Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 449-456.	1.0	20
30	Coexistence of Pyoderma Gangrenosum and Sweet's Syndrome in a Patient With Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 2865-2866.	0.2	19
31	Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2009, 50, 684-692.	1.8	19
32	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015, 29, 1927-1935.	1.0	19
33	Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2018, 32, 1423-1430.	1.0	17
34	Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2435-2443.	1.3	16
35	The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. <i>PLoS ONE</i> , 2016, 11, e0168265.	1.1	15
36	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 28-32.	0.3	15

#	ARTICLE	IF	CITATIONS
37	Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2017, 31, 89-95.	1.0	14
38	Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 16-24.	1.0	14
39	Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. <i>BMJ Open</i> , 2020, 10, e039951.	0.8	14
40	Management of HCV-related end-stage liver disease in HIV-coinfected patients. <i>AIDS Reviews</i> , 2007, 9, 131-9.	0.5	14
41	Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus "coinfected patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015, 61, 1503-1511.	3.6	13
42	Recommendations for the diagnosis and treatment of <i>Clostridioides difficile</i> infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 151-175.	0.5	13
43	Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 839-46.	0.6	12
44	High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. <i>HIV Medicine</i> , 2017, 18, 445-451.	1.0	11
45	Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2019, 33, 269-278.	1.0	11
46	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	2.9	11
47	Bilateral enophthalmos as a manifestation of HIV infection-related lipoatrophy. <i>HIV Medicine</i> , 2004, 5, 448-449.	1.0	10
48	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1351-1353.	1.3	10
49	Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg Once Daily in HIV/Hepatitis C Virus-Coinfected Patients. <i>AIDS Patient Care and STDs</i> , 2011, 25, 395-402.	1.1	9
50	Liver stiffness correlates with Child-Pugh and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1031-1032.	1.9	9
51	Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. <i>BMC Infectious Diseases</i> , 2015, 15, 557.	1.3	9
52	High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 532-535.	0.3	9
53	HAART and the liver: friend or foe?. <i>European Journal of Medical Research</i> , 2010, 15, 93.	0.9	8
54	HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. <i>Antiviral Research</i> , 2012, 95, 212-215.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1929-1936.	1.3	8
56	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 409.e5-409.e8.	2.8	8
57	Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 127-131.	0.3	7
58	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. <i>Current HIV/AIDS Reports</i> , 2020, 17, 6-17.	1.1	7
59	Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1225-1232.	1.3	6
60	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1837-1848.	0.9	6
61	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017, 18, 546-554.	1.0	6
62	Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2004, 18, 1746-1748.	1.0	5
63	Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. <i>Aids</i> , 2020, 34, 1497-1507.	1.0	5
64	Impact of COVID19 pandemic on the incidence of health-care associated <i>Clostridioides difficile</i> infection. <i>Anaerobe</i> , 2022, 75, 102579.	1.0	5
65	Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 87-91.	1.3	4
66	Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 180-186.	1.0	4
67	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. <i>Scientific Reports</i> , 2018, 8, 14905.	1.6	4
68	Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2019, 26, 48-54.	1.0	4
69	Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. <i>Scientific Reports</i> , 2020, 10, 6736.	1.6	4
70	Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection. <i>Scientific Reports</i> , 2019, 9, 9054.	1.6	2
71	High Incidence of Asymptomatic Phase I IgG Seroconversion After an Acute Q Fever Episode: Implications for Chronic Q Fever Diagnosis. <i>Clinical Infectious Diseases</i> , 2022, 74, 2122-2128.	2.9	2
72	Transient Budd-Chiari Syndrome due to Iatrogenic Subcapsular Fluid Accumulation Following Thoracocentesis. <i>American Journal of Gastroenterology</i> , 2004, 99, 2281-2282.	0.2	1

#	ARTICLE	IF	CITATIONS
73	642 BARCELONA-CLINIC-LIVER-CANCER (BCLC) STAGING AND ACTUAL THERAPY RECEIVED IN HIV-INFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), COMPARING DIAGNOSIS PRE-2006 AND 2006 AND LATER. <i>Journal of Hepatology</i> , 2011, 54, S259-S260.	1.8	1
74	Changes in the response to treatment against chronic hepatitis C between 1999 and 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1253-1257.	0.8	1
75	Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals. <i>Journal of Infection</i> , 2017, 74, 514-517.	1.7	1